GlassScriptPhysician profile
Douglas T Ford
NPI 1306807177
$19,596.99
in general payments reported to CMS, 2019-2025
18 companies · $4,303 in 2025
The $4,303 reported for 2025 was more than what 93% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,518 · 2020: $147 · 2021: $505 · 2022: $378 · 2023: $3,235 · 2024: $5,512 · 2025: $4,303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,800.00 |
| Food and Beverage | $1,250.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Research LLC | $11,800.00 | 2023-2025 | |
| Alcon Vision LLC | $6,269.95 | 2019-2025 | Clareon, Rocklatan, Simbrinza |
| Abbvie INC. | $503.66 | 2022-2025 | |
| Allergan, INC. | $340.93 | 2019-2022 | |
| Shire North American Group INC | $179.97 | 2019 | |
| Novartis Pharmaceuticals Corporation | $110.93 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $71.52 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $69.21 | 2022-2024 | Vyzulta, Zylet, Miebo |
| Ocular Therapeutix, INC. | $49.59 | 2021-2023 | Dextenza |
| Sun Pharmaceutical Industries INC. | $47.15 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $31.01 | 2019-2020 | |
| Harrow Eye, LLC | $20.74 | 2023 | Iheezo |
| Sight Sciences, INC. | $19.74 | 2022 | |
| Omeros Corporation | $19.52 | 2021 | |
| Dompe US, INC. | $17.82 | 2024 | Oxervate |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $17.34 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $14.02 | 2019 | |
| Glaukos Corporation | $13.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.